In an effort to see if Ivermectin would be effective in patients hospitalized with Covid-19, the authors gave half of them 12 mg of the drug for 3 (three) days. There were 82 patients in each group with “mild to moderate” illness.
NOTE: As they were all in the hospital, it is unlikely they were “mildly” sick by the usual definition, and their symptoms were not defined. Nevertheless, it was noted that only 3 of each group (3.6%) needed ventilation.
In spite of the short treatment time with a small dose of the drug, there was a trend toward a favorable outcome, although it did not reach significance.
NOTE: Why they were given the experimental drug (in addition to “usual care”) for only 3 days was not discussed, but in their Discussion they did recommend increasing the dosage in future trials.
Conflict of Interest: None declared, and none of the authors appeared to be connected to vaccine manufacturers.
Research Square, Preprints DOI: 10.21203/rs.3.rs-950352/v1 The intent of this study was to compare treating Covid-19 with Ivermectin alone, or with a combination of Ivermectin, Hydroxychloroquine, and Azithromycin (HIA therapy). In addition, both groups received "standard of care" treatment which included Zinc and Vitamin C, as well as Oxygen when needed.…
International Journal of Infectious Diseases, March 2022. 116 (Supplement), S40. Efimenko, Nackeeran, Jabori, Gonzalez Zamora, Danker, Singh This study followed 41,608 patients with Covid. 40,536 were treated with Remdesivir, and 1,072 were treated with Ivermectin. Results were controlled for a number of possible confounds such as diabetes, Ivermectin had a 70%…
Archivos de Bronconeumologia, 2020;56(12):816–830 The authors describe a clinical study in Bangladesh, in which half of 248 patients (without underlying conditions) received standard care, while half received standard care plus ivermectin. A 12 mg dose of ivermectin was given just once on the first day of hospitalization. The ivermectin was…